Oral dextrose gel probably leads to lower separation from mother for treatment of hypoglycaemia before… compared with control (moderate certainty).
IV iron isomaltoside showed no clear difference in number of responders ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
Intravenous iron therapy may leads to higher ferritin preoperatively postintervention (ng/L) compared with oral iron therapy (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Intravenous iron therapy may leads to higher haemoglobin levels at end of preoperative treatment (g/dL) compared with oral iron therapy (low certainty).
Patient‐centred outcomes for oral showed no clear difference in death (all causes) compared with IV iron (low certainty).
It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
(Infant outcomes) Any supplements containing iron showed no clear difference in low birthweight (less than 2500 g) (ALL) compared with same supplements without iron or no treatment/placebo (no iron or… (low certainty).
(Infant outcomes) Any supplements containing iron showed no clear difference in preterm birth (less than 37 weeks of gestation) (ALL) compared with same supplements without iron or no treatment/placebo (no iron or… (moderate certainty).
(Infant outcomes) Any supplements containing iron showed no clear difference in neonatal death (within 28 days after delivery) (ALL) compared with same supplements without iron or no treatment/placebo (no iron or… (low certainty).
(Infant outcomes) Any supplements containing iron showed no clear difference in congenital anomalies (ALL) compared with same supplements without iron or no treatment/placebo (no iron or… (low certainty).
It is very uncertain whether (Maternal outcomes) Any supplements containing iron changes maternal severe anaemia at any time during second and third… compared with same supplements without iron or no treatment/placebo (no iron or… (very low certainty).